Sign In
Buy ARWR
$84.65
-2.67 (-3.06%)
At Close: Jul 31, 2026
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of z
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran,
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Affinity Asset Advisors LLC
04:05am, Saturday, 25'th Jul 2026
Affinity Asset Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 185.7% during the first quarter, according to its most recent disclosure with the Securities
California Public Employees Retirement System Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
04:43am, Friday, 24'th Jul 2026
California Public Employees Retirement System purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the first quarter, according to its most recent Form 13F filin
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat
02:25pm, Wednesday, 22'nd Jul 2026
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock is trading higher on Wednesday as the company revealed successful topline outcomes from its late-stage SHASTA-3 and SHASTA-4 trials evaluating plozas
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential
01:28pm, Wednesday, 22'nd Jul 2026
Arrowhead Pharmaceuticals surged nearly 20% after strong Phase 3 results for plozasiran in severe hypertriglyceridemia, showing 79–81% triglyceride reductions and significant acute pancreatitis risk
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
10:24am, Wednesday, 22'nd Jul 2026
Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Red
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of pl
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran
These major drug stocks rally after Trump's zero tariff announcement
06:31am, Wednesday, 22'nd Jul 2026
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
07:30am, Tuesday, 21'st Jul 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discus
This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
07:46am, Tuesday, 14'th Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
04:42pm, Monday, 29'th Jun 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
08:15am, Thursday, 25'th Jun 2026
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical asse
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO�
